RET and non-small cell lung carcinoma: Initial treatment efforts with MKIs—such as cabozantinib, vandetanib, and lenvatinib—showed limited efficacy and were associated with significant off-target toxicities, making them suboptimal options for RET-rearranged NSCLC [18,214,215,216].